▶️ "Immune imprinting induced by wildtype (WT)-based vaccination would compromise the antibody response to Omicron-based boosters"biorxiv.org/content/10.110…
3) ▶️ Single Omicron-boosting is heavily limited by immune imprinting, especially when using variants antigenically distinct from WT, like XBB"
▶️ "Repeated Omicron infections could also alleviate WT-vaccination-induced immune imprinting and generate high neutralizing titers ...
4) ...against XBB.1.5 and XBB.1.16"
▶️ "Our findings suggest the WT component should be abandoned when updating COVID-19 vaccine antigen compositions to XBB lineages, and those who haven’t been exposed to Omicron yet should receive two updated vaccine boosters."
5) Fig. 2 | Humoral immune imprinting after repeated Omicron infections in humans.
6) Fig. 3 B cell immune imprinting after repeated Omicron infections.
7) Fig. 4 Epitope distribution and characterization of mAbs elicited by Omicron BTI and reinfection
8) Fig. 5 | Estimate the evolutionary trends of XBB.1.5 RBD from DMS profiles.
9) Fig. 6 Combination of escape mutations evades XBB.1.5-neutralizing antibodies from reinfection.
10) Extended Data Fig. 7 SPR sensorgrams for affinity of hACEZ and SARS-CoV-2 mutants RBD
11) Thanks for reading 🙏 and let see the reaction of the experts on this subject 😁
WHY INFECTIONS by BACTERIA, VIRUSES and FUNGI will INCREASE in the FUTURE ? 🧵
2 recent studies highlights important concerns about the rise of infections caused by bacteria, viruses, fungi and the role of COVID-19
2) One study focuses on antibiotic resistance, where bacteria become resistant to medicines meant to kill them. This often happens due to the overuse of antibiotics in healthcare and agriculture, along with a lack of new antibiotics being developed.
3) As these bacteria evolve and become harder to treat, even common infections could lead to severe health problems.
The second study discusses how climate change and urban growth are contributing to the increase in viral and fungal infections.
2) Astrocytes are the brain cells that can be infected and support the growth of the SARS-CoV-2 virus. This likely contributes to the neurological symptoms of COVID-19.
3) Experiments show ketamine, an anesthetic, can reduce astrocyte infection by earlier SARS-CoV-2 variants, but not newer variants. Ketamine does this by decreasing the virus's entry receptor and replication in astrocytes.
2) This first figure helps explain the first key mechanisms contributing to cognitive impairment in COVID-19 patients:
▶️ Direct viral entry and brain injury is shown in the first panel.
▶️ The role of hypoxia (lack of oxygen) in cognitive decline is depicted in the second panel
3) ▶️ The widespread systemic inflammation caused by COVID-19 is illustrated in the third panel.
For CHILDREN, the risk of LONG COVID after a SECOND INFECTION is 2.08 TIMES GREATER compared to the FIRST INFECTION. medrxiv.org/content/10.110…
2) Let's summarize first this study :
The researchers used medical records from 40 children's hospitals in the US between January 2022 and October 2023. They compared the risk of long-term issues in those with a second COVID-19 infection versus their first infection.
3) Results showed that children with a 2nd infection had a significantly higher risk of various long-term problems, including:
- Heart issues like inflammation and abnormal heart rhythms
- Changes in taste and smell
- Blood clots
- Kidney problems
- Fatigue and muscle/joint pain
What a "CLEVER" SARS-COV-2 virus !
... which induced a P812S mutation in a chronically ill individual, that is somewhat less pathogenic but enables the virus to infect a larger population. biorxiv.org/content/10.110…
2) This study looks at how a single mutation, called P812S, in the SARS-CoV-2 virus can have different effects. The P812S mutation was found in a person with a long-term COVID-19 infection.
3) The study found that the P812S mutation:
- Reduced the ability of the virus to enter cells and cause them to fuse together (form syncytia). This is linked to less severe COVID-19 disease.
- Helped the virus evade antibodies that target the fusion peptide region of the spike.